HEARTSEED
Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 2 billion JPY at Series D round, bringing its total financial backing to 10.2 billion JPY (approx. $74 million) since it was founded in 2015.
New investors are Japan Co-Invest IV Limited Partnership (GP: Sumitomo Mitsui Trust Investment), Arcus South East Asia, Atsushi Sakano (Partner of Aspex Management), Koei Tecmo Capital, Nikon-SBI Innovation Fund, etc. Among the existing investors, SMBC Venture Capital, Private Equity Co-Invest II Limited Partnership (GP: Sumitomo Mitsui Trust Investment), UTokyo Innovation Platform, Medical Incubator Japan, Keio Innovation Initiative (KII), etc. participated this round.
Heartseed plans to use the new funds to complete the Phase 1/2 clinical trial of our lead asset, HS-001 for HF in Japan, as well as to establish an organization for its launch. In addition, Heartseed will also examine a less invasive administration such as transendocardial injection using a catheter for global development by Novo Nordisk.
“Heartseed achieved the first human dosing of HS-001 in December 2022, and initial safety and early sings of efficacy are being confirmed.” said Keiichi Fukuda, co-founder and CEO at Heartseed. “The commitment from both new and existing investors in this round is a strong validation of our technology and strategic vision. With their support, we look forward to accelerating our development to deliver potentially curative therapy for heart failure across the globe.”
About HS-001 and LAPiS Study
HS-001, is allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. The expected mechanism of action is that the transplanted cardiomyocytes electrically couple with the patient's myocardium to improve cardiac output by remuscularization, and secretion of angiogenic factors to form new blood vessels around the transplant site (neovascularization).
LAPiS Study a 52-week, phase 1/2, open-label, dose-escalation study in patients with advanced heart failure caused by ischaemic heart disease, conducted at various study sites in Japan. The primary endpoint of the study is safety at 26 weeks post-transplantation, and secondary efficacy endpoints include left ventricular ejection fraction and myocardial wall motion.
For details: https://www.heartseed.jp/en/index.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005069/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LRN Sponsors 2025 Nordic Ethics & Compliance Survey to Advance Region-Specific Insights on Responsible Business Conduct24.11.2025 10:00:00 CET | Press release
LRN and Nordic Business Ethics partner to elevate region-specific insights that strengthen global E&C effectiveness LRN Corporation, a leader in ethics and compliance (E&C) solutions, announced its sponsorship of the 2025 Nordic Ethics & Compliance Survey, an annual study by Nordic Business Ethics examining how organizations across the Nordic region integrate ethics, responsibility, and compliance into daily decision-making. LRN’s sponsorship supports the survey’s mission to highlight regional insights that enrich global understanding of workplace ethics. The partnership reflects LRN’s belief that effective E&C programs are not a one-size-fits-all solution and must be informed by regional cultural norms and organizational identity. The survey data shows that while Nordic organizations excel in values-driven ethics, their experience mirrors a global trend of increased regulatory expectations and company growth straining operational systems and governance structures. “Nordic organization
IonQ Appoints Dr. Marco Pistoia as CEO of IonQ Italia to Spearhead Strategic Quantum Initiatives Across the Country24.11.2025 09:00:00 CET | Press release
Industry veteran Pistoia to drive enterprise and research engagement as IonQ deepens investment in Italy’s quantum future IonQ (NYSE: IONQ), the world’s leading quantum company, today announced the appointment of Dr. Marco Pistoia, Ph.D., as Chief Executive Officer of IonQ Italia S.r.l., a wholly owned subsidiary. Dr. Pistoia will lead IonQ’s strategic initiatives in Italy, building on the company’s momentum as the world’s only full-stack quantum platform provider across quantum computing, quantum networking, quantum sensing, and quantum security. IonQ Italia will help establish Italy as a dynamic powerhouse in the global quantum landscape. Dr. Pistoia and his team will focus on expanding access to IonQ’s advanced quantum systems for Italian enterprises, research institutions, and government partners. The team will be tasked with driving innovation in quantum applications for key sectors such as finance, energy, aerospace, defense, pharmaceuticals, and advanced manufacturing. “Italy is
Global Youth Invited To Apply for Doha Debates Ambassador Program24.11.2025 07:45:00 CET | Press release
Unique virtual program empowers young changemakers with communication, collaboration, and problem-solving skills Qatar Foundation’s Doha Debates is inviting global youth ages 18–26 to apply for the eighth cohort of its international ambassador program. This 12-week virtual experience empowers participants to engage in constructive dialogue, collaborate on solutions to global challenges and form lasting relationships with other emerging leaders. The application deadline is December 15, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251123068415/en/ Global youth are invited to apply for the Doha Debates Ambassador Program, a unique virtual experience that equips young changemakers with communication, collaboration, and problem-solving skills. (Photo: AETOSWire) The upcoming cohort begins with a four-week Community of Practice from January 20 to February 10, 2026, followed by the official Ambassador Program from February
Brown Brothers Media Acquires European Startup Media Platform Silicon Canals24.11.2025 03:23:00 CET | Press release
Brown Brothers Media, a Singapore-based digital publisher, announces the acquisition of SiliconCanals.com, the European technology startup media platform and community founded by Remco Janssen and operated under Proudly Media. The six-figure, asset-based deal marks a new chapter for the 11-year-old Dutch media brand, which has grown into one of Europe’s leading voices in the startup and innovation ecosystem. Founded in 2014, Silicon Canals has established itself as a go-to source for news and insights on Europe’s tech, venture capital, and startup scene. The acquisition follows recent shifts in the European tech media landscape, including the closure of The Next Web’s editorial operations and MeOut Group’s earlier acquisition of EU-Startups. “After more than a decade building Silicon Canals into a trusted platform connecting Europe’s founders, innovators, and investors, it was time to pass the baton to a full-fledged, long-term media house,” said Remco Janssen, founder and CEO of Proud
IFF Introduces Smart Dosing Robot to Transform Fragrance Production24.11.2025 02:00:00 CET | Press release
New technology delivers quicker, more precise creative sampling for IFF customers across Greater Asia. IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences, has implemented the Colibri robot in its Chin Bee production facility. This advanced industrial dosing system can produce fragrance sample batches on demand in minutes, reimagining and expediting the fragrance development journey for local, regional and global customers in Greater Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251123090457/en/ Photo credit: IFF - Colleagues at IFF Chin Bee with the site's new smart-dosing robot. The new robotic system, installed at the company's cross-category Scent and Taste production plant in Chin Bee, Singapore, accelerates the path from ideation to formulation for fragrance creation. Replacing the previous system, it handles multiple ingredients simultaneously, operates four times
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom